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The effect of maintenance immunosuppression medication on
the change in kidney allograft function.
Background. The optimum maintenance immunosuppres-
sion regimen for kidney transplant recipients is uncertain. In
this study we determined the effect of maintenance immuno-
suppression medications on the rate of kidney allograft function
loss defined by the annualized change in glomerular filtration
rate (GFR).
Methods. We studied 40,963 first kidney only transplant re-
cipients between 1987 and 1996 with allograft survival of at
least two years in the United States Renal Data System. Lin-
ear regression methods were applied to serial GFR estimates
after transplantation to determine the annualized change in
GFR. Patients were classified according to the type of main-
tenance calcineurin and purine metabolism inhibitor received
after transplantation. Multiple linear regression was used to
determine the independent effect of maintenance immuno-
suppression medications on the annualized change in GFR
(mL/min/1.73m2/year).
Results. Compared to patients who received cyclosporine mi-
croemulsion (Neoral), a slower decline in GFR was observed
in tacrolimus-treated patients (1.60 mL/min/1.73m2/year, 95%
CI 1.22–1.97, P < 0.001) and patients who did not receive cal-
cineurin inhibitors (0.82 mL/min/1.73m2/year, 95% CI 0.08–
1.56, P = 0.03). In contrast, compared to compared to patients
who received Neoral, a faster decline in GFR was observed
in patients who received the original oil-based formulation of
cyclosporine (Sandimmune) (–0.16 mL/min/1.73m2/year, 95%
CI −0.003 to −0.32, P = 0.04) and patients with unknown cal-
cinuerin inhibitor exposure (–2.11 mL/min/1.73m2/year, 95% CI
−2.27 to −1.95, P < 0.001). Compared to patients who received
azathioprine, patients who received mycophenolate mofetil
(MMF) had a slower decline in GFR (0.61 mL/min/1.73m2/year,
95% CI 0.14–1.08, P = 0.01) and patients with unknown purine
metabolism inhibitor exposure had a faster decline in GFR
(−0.61 mL/min/1.73m2/year, 95% CI −0.75 to −0.47, P <
0.001.) In a subgroup analysis of patients who received a
transplant after 1993, the decline in GFR was slower for
tacrolimus compared to neoral treated patients (1.64 mL/min/
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1.73m2/year, 95% CI 1.15–2.14, P < 0.001) but was not dif-
ferent for MMF compared to azathioprine-treated patients
(0.24 mL/min/1.73m2/year, 95% CI −0.38–0.85, P = 0.45).
Conclusion. Tacrolimus and MMF were the calcineurin in-
hibitor and purine metabolism inhibitor associated with the
most favorable effects on rates of change in allograft function.
Because most transplant recipients establish a low baseline level
of allograft function, the effect of immunosuppression medica-
tion on GFR decline should be considered when selecting a
maintenance immunosuppression regimen.
With the introduction of new medications in the 1990s,
several options now exist for maintenance immunosup-
pression in kidney transplant recipients. New immuno-
suppression medications were introduced based on their
ability to reduce the incidence of acute rejection and
to demonstrate short-term outcomes of one-year pa-
tient and allograft survival that were at least equivalent
to those achieved with the use of established immuno-
suppression medications [1–3]. However, with the suc-
cess of kidney transplantation established in the short
term, the focus of transplant clinicians has shifted toward
improving long-term outcomes. In prospective studies,
researchers have been unable to demonstrate an im-
provement in long-term allograft survival with newer
maintenance immunosuppression medications [4]. Al-
though registry data have shown a modest improvement
in long-term allograft survival, it is uncertain whether this
improvement is related to the long-term benefits of re-
duced acute rejection, improvements in the overall care
of transplant recipients, or the type of maintenance im-
munosuppression [5].
Differences in long-term allograft survival between
maintenance immunosuppression regimens are likely to
be small, and therefore surrogate markers of immuno-
suppression medication efficacy are required. The annu-
alized change in glomerular filtration rate (GFR) is the
preferred method by which to monitor the progression of
kidney function decline in patients with chronic kidney
disease, including transplant recipients [6]. We recently
characterized the annualized change in GFR among long-
term kidney transplant recipients [7]. In this study, we
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determined the effect of maintenance immunosuppres-
sion medications on the annualized change in GFR in a
large group of kidney transplant recipients with at least
two years of allograft survival.
METHODS
Study population
We studied all adult (18- to 70-year-old) first, kidney
only transplant recipients between January 1987, and
September 1996, with at least two years of allograft sur-
vival in the TXUNOS standard analysis file of the United
States Renal Data System (USRDS). Study patients had
complete follow-up information in the TXFU-UNOS and
Patients standard analysis files. We excluded patients with
less than three serum creatinine measurements in the first
two post-transplant years to permit a precise estimate
of the annualized change in GFR [8]. In addition, pa-
tients with an estimated GFR <10 mL/min/1.73m2 during
the first two post-transplant years were excluded because
most patients with GFR at this level would return to dialy-
sis [9]. Similarly, patients with GFR >100 mL/min/1.73m2
during the first two transplant years were also excluded
because such patients are considered at low risk for pro-
gression of chronic kidney disease [6].
Data sources
The TXUNOS standard analysis file contains the
date of transplantation as well as donor and recipient
characteristics. The TXFU-UNOS standard analysis file
contains serum creatinine measurements and immuno-
suppression medication use at the time of transplanta-
tion, six months after transplantation, and then yearly
thereafter. The Patients standard analysis file contains
the dates of recipient birth, death, and allograft loss.
Analytical methods
Patient characteristics were described as frequencies
or as the mean ± standard deviation, unless otherwise
indicated. Characteristics of study patients were com-
pared with those of excluded patients using the chi-square
test for categorical variables and t test for continuous
variables.
Patients were grouped by the type of maintenance cal-
cineurin inhibitor [original oil-based formulation of cy-
closporine (Sandimmune), cyclosporine microemulsion
(Neoral), or tacrolimus] and the type of maintenance
purine metabolism inhibitor [azathioprine, mycophe-
nolate mofetil (MMF)] received, and any change in
medication during follow-up was noted. The types of
maintenance immunosuppression medications were clas-
sified as unknown for patients in whom these variables
were missing or inconsistently recorded. Patient charac-
teristics in the different maintenance immunosuppres-
sion medication groups were compared with the chi-
square test for categorical variables and analysis of vari-
ables (ANOVA) for continuous variables.
For each patient, the GFR was estimated serially after
transplantation with an equation derived from the Modi-
fication of Diet in Renal Disease (MDRD) Study [10], as
recommended by recent guidelines [6]. The annualized
change in GFR (mL/min/1.73m2/year) for each patient
was then determined using simple linear regression as
previously described [7]. At least three GFR estimates
over two consecutive years of follow-up were required to
calculate the annualized change in GFR.
The mean and 95% CI of the change in GFR was de-
scribed for patients in each of the maintenance immuno-
suppression medication groups. For individual patients,
the change in GFR could only be assigned to a
particular immunosuppression medication if the same
medication was administered during the minimum two
consecutive years required to calculate the annualized
change in GFR. Therefore, patients who changed im-
munosuppression medications during follow-up were
grouped according to whether the change in medica-
tion occurred before the first, or after the first two post-
transplant years.
The independent association of the type of mainte-
nance immunosuppression medication with the annual-
ized change in GFR was determined in multiple linear
regression analysis. For the purposes of the multiple
regression analysis, the immunosuppression medication
(calcineurin or purine metabolism inhibitor) for patients
who changed medications during the first two years were
classified as unknown because the annualized change in
GFR during this period could not be associated with a
single type of calcineurin or purine metabolism inhibitor.
To prevent bias due to factors that might trigger a change
in immunosuppression medication, patients who changed
medication after the first two post-transplant years were
classified according to the initial medication they re-
ceived, and the change in GFR was determined using
only the GFR estimates available before the medication
change.
In addition to the type of maintenance immunosupp-
pression medication, the other variables included in the
multivariate regression analysis were donor, recipient,
and immunologic factors that demonstrated a statisti-
cally significant association (P <0.05) with the annualized
change in GFR in simple linear regression analysis. In ad-
dition, we included the duration of follow-up to account
for improvements in transplant care that have occurred
over time (era effect) and for any survivor bias. The effect
of different combinations of calcineurin inhibitors and
purine metabolism inhibitors on the annualized change
in GFR was explored with the use of interaction terms.
Cook’s distance was used to identify points of in-
fluence, and the tolerance statistic was used to detect
694 Gill et al: The effect of immunosuppression on allograft function
N = 40,963
study patients
Received same
medication during
follow-up
N = 24,793
Changed
medication during
follow-up
N = 5,289
Received
no or unknown
medication during
follow-up
N = 10,881
Sandi-
mmune
N = 14,014
Neoral
9,592
Tacrolimus
 N = 1,187
Early change
(changed
medication in
first  2
post-transplant
year)
N = 1,586
Late change
(changed
medication 
after first 2
post-transplant
year)
N = 3,703
No medica-
tion
N = 244
Unknown
medication
10,637
A
N = 40,963
study patients
Received same
medication during
follow-up
N = 25,208
Changed 
medication during
follow-up
N = 8,021
Received
no or unknown
medications during
follow-up
N = 7,734
No medication
N = 3,099
Unknown
medication
N = 4,635
Azathioprine
N = 24,592
Mycopheno-
late
mofetil
N = 616
Changed
medication
in first 2 years
N = 3,811
Changed
medication
after 2 years
N = 4,210
B
Fig. 1. Patient disposition according to main-
tenance calcineurin and purine metabolism
inhibitor use.
colinearity between independent variables considered in
the multiple linear regression analysis [11, 12]. Colinear-
ity was detected for the variables transplant year and du-
ration of follow-up. Because duration of follow-up could
explain both a survivor bias and an era effect and resulted
in better model performance (higher r2), we chose to in-
clude this variable instead of transplant year. In addition,
because tacrolimus and MMF use was more prominent
after 1993, we performed a separate multiple regression
analysis restricted to patients who received a transplant
after this time. This subgroup analysis was performed to
determine whether the observed differences between im-
munosuppressive medications were confounded by dif-
ferences in transplant care over time not accounted for in
the overall multiple regression analysis. Statistical analy-
ses were performed with SAS software version 8.2 (Cary,
NC, USA).
RESULTS
There were 54,582 eligible patients with complete
follow-up information available, 11,732 of whom were ex-
cluded because they had less than three GFR estimates
during the first two post-transplant years. Another 1887
patients were excluded because at least one GFR esti-
mate in the first two post-transplant years was <10 or
>100 mL/min/1.73m2. The study patients and excluded
patients had clinically similar demographic characteris-
tics: age, 43 versus 44 years (P = 0.67); male gender, 60%
in both groups; white race, 75% versus 72% (P < 0.01);
diabetes, 21% in both groups; cadaveric donor, 72% ver-
sus 70% (P < 0.01).
Figure 1 shows the classification of patients according
to the type of maintenance immunosuppression medi-
cation received. There were 24,793 (60%) patients who
received the same type of calcineurin inhibitor during
follow-up (Fig. 1A): Sandimmune (N = 14,014), Neo-
ral (N = 9592), and tacrolimus (N = 1187). Among
the 5289 (13%) patients who changed the type of cal-
cineurin inhibitor during follow-up, 1586 changed be-
fore, and 3703 changed after the first two post-transplant
years. There were 10,881 (27%) patients with no (N =
244) or unknown (N = 10,637) calcineurin inhibitor expo-
sure. There were 25,208 (61%) patients who received the
same type of purine metabolism inhibitor during follow-
up (Fig. 1B): azathioprine (24,592) and MMF (N = 616).
Among the 8021 (20%) patients who changed purine
metabolism inhibitors during follow-up, 3811 changed be-
fore, and 4210 changed after the first two post-transplant
years. There were 7734 (19%) patients with no (N = 3099)
or unknown (N = 4635) exposure to purine metabolism
inhibitors.
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Table 1. Patient characteristics in calcineurin inhibitor groups
Changed
calcineurin None/
Characteristic Sandimmune Neoral Tacrolimus inhibitor unknown P value
Number 14,014 9592 1187 5289 10,881
Recipient age 43 ± 12 44 ± 12 44 ± 12 43 ± 12 42 ± 12 <0.001
Male gender % 59% 61% 61% 58% 61% <0.001
African American race % 19% 18% 20% 21% 23% <0.001
Cause of kidney disease
GN 34 33 28 34 36 <0.001
Other 22 20 25 21 19 <0.001
Diabetes 20 21 22 21 21 0.004
Htn 14 15 16 14 15 0.57
PKD 10 11 9 10 9 <0.001
Donor age 33 ± 15 34 ± 15 35 ± 17 34 ± 15 33 ± 15 <0.001
Cadaveric donor % 72 71 76 69 76 <0.001
Zero HLA mismatch % 11 12 10 12 10 <0.001
Zero % panel-reactive 66 67 58 68 60 <0.001
antibodies %
Delayed graft function % 14 15 18 16 19 <0.001
Rejection in first three 21 19 20 20 30 <0.001
months %
GFR at one year after 50 ± 15 50 ± 15 45.3 ± 16.5 50 ± 15 48 ± 16 <0.001
transplant mL/min/1.73m2
Transplant year % <0.001
1987–89 17 10 1 14 44
1990–3 56 43 30 44 50
1994–6 27 47 69 42 6
Abbreviations are: GN, glomerulonephritis; Htn, hypertension; PKD, polycystic kidney disease; HLA, human lymphocytic antigen; GFR, glomerular filtration rate.
Table 1 shows the characteristics of the study pa-
tients who received different types of maintenance cal-
cineurin inhibitor during follow-up; it also shows that the
demographic and donor characteristics of patients who
received different types of calcineurin inhibitors were
clinically similar. The GFR at one year after transplan-
tation was lowest in patients who received tacrolimus.
Table 2 shows that the demographic and donor charac-
teristics were also clinically similar among patients in the
Table 2. Patient characteristics in purine metabolism inhibitors
Mycophenolate None/
Characteristic Azathioprine mofetil Changed unknown P value
Number 24,592 616 8021 7734
Recipient age 42 ± 12 44 ± 12 44 ± 12 44 ± 12 <0.001
Male gender % 61 60 59 59 0.12
African American race % 20 26 22 19 <0.001
Cause of kidney disease %
GN 34 31 33 35 0.007
Other 20 24 21 20 0.25
Diabetes 22 20 19 20 <0.001
Htn 14 17 17 15 <0.001
Polycystic 9 9 11 10 0.001
Donor age 33 ± 15 35 ± 16 35 ± 15 33 ± 15 <0.001
Cadaveric donor % 71 71 73 75 <0.001
Zero HLA mismatch % 12 13 11 11 0.03
0% panel-reactive antibodies % 65 72 67 61 <0.001
Delayed allograft function % 15 15 16 18 <0.001
Rejection in first 3 months % 23 13 21 23 <0.001
GFR at one year mL/min/1.73m2 50 ± 15 50 ± 16 49 ± 16 49 ± 16 <0.001
Transplant year % <0.001
1986–89 24 1 11 28
1990–93 52 13 43 48
1994–6 24 86 46 24
Abbreviations are: GN, glomerulonephritis; Htn, hypertension; HLA, human lymphocytic antigen; GFR, glomerular filtration rate.
different purine metabolism groups, although the use of
MMF was higher among African American patients. The
patients who received MMF also had the lowest incidence
of acute rejection.
In study patients, the baseline GFR (measured at six
months after the time of transplantation) was 49.6 ±
15.4 mL/min/1.73m2. Patients were followed for 5.7 ±
2.3 years (median 5.3 years) from the time of transplan-
tation. There were 5458 (13%) patients who returned to
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Table 3. Annualized change in GFR among different maintenance
immunosuppression groups (univariate analysis)
Change in GFR
Maintenance (mL/min/1.73m2/year)
immunosuppression (95% CI)
Calcineurin inhibitors
Sandimmune −0.62 (−0.71, −0.53)
Neoral −0.80 (−0.93, −0.68)
Tacrolimus 0.76 (0.35, 1.18)
Changed calcinuerin inhibitor
During first 2 years of transplantation −1.41 (−1/84, −0.97)
After 2 first 2 years of transplantation −0.34 (−0.54, −0.15)
None 0.67 (0.25, 1.09)
Unknown −2.96 (−3.11, −2.81)
Purine metabolism inhibitors
Azathioprine −1.14 (−1.21, −1.06)
MMF −1.03 (−1.75, −0.32)
Changed purine metabolism inhibitor
During first 2 years of transplantation −1.41 (−1.67, −1.16)
After 2 first 2 years of transplantation −0.82 (−1.01, −0.63)
None −0.57 (−0.79, −0.35)
Unknown −2.39 (−2.58, −2.20)
dialysis or received repeat transplants and 4397 (11%)
patients who died with allograft function. The median
number of GFR estimates used to calculate the annual-
ized change in GFR was 5 (range 3–11).
Table 3 shows the annualized change in GFR among
patients who received different types of maintenance im-
munosuppression medication. Among the calcineurin in-
hibitor groups, patients who received tacrolimus or no
calcineurin inhibitor showed an increase in annualized
GFR, while all other groups had a decrease in annu-
alized GFR. Among patients who changed calcineurin
inhibitors, patients who changed medication within the
first two post-transplant years had a more rapid decline
in annualized GFR. Patients with unknown calcineurin
inhibitor exposure had the most rapid decline in the
annualized change in GFR. All patients in the purine
metabolism inhibitor groups showed a decline in the an-
nualized change in GFR. The decline in the annualized
change in GFR was most rapid in patients with unknown
purine metabolism inhibitor exposure.
The results of the multiple linear regression analysis
to determine the independent effect of maintenance im-
munosuppression on the annualized change in GFR are
shown in Figure 2. In addition to the type of maintenance
immunosuppression medication, the multiple regression
included the following variables, which demonstrated a
significant association with the change in GFR (P < 0.05)
in univariate analysis: recipient age, gender, race, cause
of end-stage renal disease, donor age, donor type (cadav-
eric or live donor), human lymphocytic antigen (HLA)
match, panel reactive antibody titer (PRA), acute rejec-
tion (within the first three post-transplant months), de-
layed graft function (dialysis in the first post-transplant
week) GFR at six months after transplantation, duration
of follow-up, and whether there was a change in immuno-
suppression during follow-up.
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Fig. 2. The annualized change in glomerular filtration rate (GFR) and
95% CI for patients who received different maintenance calcineurin
and purine metabolism inhibitors. The medication effects were calcu-
lated from a multiple linear regression analysis that included donor,
recipient, and immunologic factors. Neoral (A) and azathioprine (B)
are the reference calcineurin and purine metabolism inhibitors.
Compared to patients who received cyclosporine mi-
croemulsion (Neoral), a slower decline in GFR was
observed in tacrolimus-treated patients (1.60 mL/min/
1.73m2/year, 95% CI 1.22–1.97, P < 0.001) and patients
who did not receive calcineurin inhibitors (0.82 mL/
min/1.73m2/year, 95% CI 0.08–1.56, P = 0.03). In con-
trast, compared to patients who received Neoral, a faster
decline in GFR was observed in patients who received the
original oil based formulation of cyclosporine (Sandim-
mune) (−0.16 mL/min/1.73m2/year, 95% CI −0.003 to
−0.32, P = 0.04) and patients with unknown calcineurin
inhibitor exposure (−2.11 mL/min/1.73m2/year, 95%
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CI −2.27 to −1.95, P < 0.001). Compared to patients
who received azathioprine, patients who received MMF
had a slower decline in GFR (0.61 mL/min/1.73m2/year,
95% CI 0.14–1.08, P = 0.01) and patients with unknown
purine metabolism inhibitor exposure had a faster de-
cline in GFR (–0.61 mL/min/1.73m2/year, 95% CI −0.75
to −0.47, P < 0.001).
Similar results for tacrolimus- and MMF-treated pa-
tients were found in the multiple regression analysis re-
stricted to patients who received a transplant after 1993.
In this subgroup analysis, compared to patients who re-
ceived Neoral, a slower decline in GFR was observed
in tacrolimus treated patients (1.64 mL/min/1.73m2/year,
95% CI 1.15–2.14, P < 0.001). Compared to azathioprine-
treated patients, patients who received MMF had a slower
decline in GFR (0.24 mL/min/1.73m2/year) but this dif-
ference was not statistically significant (95% CI −0.38
−0.85, P = 0.45). We studied whether the various combi-
nations of calcineurin inhibitors and purine metabolism
inhibitors had an effect on the change in GFR with the
use of interaction terms. No combination of calcineurin
inhibitor and purine metabolism inhibitor had a signifi-
cant (P < 0.05) effect on the annualized change in GFR.
DISCUSSION
The optimum maintenance immunosuppression reg-
imen for kidney transplant recipients is an area of
ongoing research. A number of factors, including the
potency of immunosuppression, side effect profile, cost,
and the effect on allograft function should be considered
when choosing one maintenance immunosuppression
medication over another [13]. Prospective trials of new
immunosuppression medications were designed to show
differences in short-term outcomes, but were not pow-
ered to show differences in long-term allograft survival.
Therefore, there is little information about the effect of
maintenance immunosuppression medication on long-
term allograft function.
In this study of long-term kidney transplant recip-
ients in the USRDS, we determined the association
between different maintenance immunosuppression
medications and a surrogate marker of long-term al-
lograft survival, the annualized change in GFR. We
considered calcineurin and purine metabolism inhibitors
separately. Compared to patients who received Neoral,
patients who received tacrolimus or no calcineurin in-
hibitor appeared to have less rapid decline in GFR, while
patients who received Sandimmune or patients with un-
known calcineurin inhibitor exposure had a more rapid
decline in GFR. In our analysis of purine metabolism
inhibitors, in which patients who received azathioprine
were the reference group, patients who received MMF
had a less rapid decline in GFR, while patients with un-
known purine metabolism inhibitor exposure had a more
rapid decline in GFR. The association between MMF use
and the annualized change in GFR was modest and did
not remain statistically significant in the subgroup analy-
sis of patients who received a transplant after 1993. There
was no evidence that the association between choice of
calcineurin inhibitor and the annualized change in GFR
was influenced by the purine metabolism inhibitor used
or vice versa.
Neither prospective trials nor registry data have
demonstrated a significant difference in allograft sur-
vival between tacrolimus- and Neoral-treated patients
[1, 14]. However, the difference in allograft survival asso-
ciated with a particular calcineurin inhibitor is likely to be
small, and a large trial with prolonged follow-up would
be required to demonstrate such a difference. The slower
rate of GFR decline in tacrolimus-treated patients in this
study may be in part related to differences in hyperten-
sion and drug levels, which were not accounted for in this
study. Hypertension is less common among tacrolimus-
treated patients [15, 16]. Similarly, therapeutic monitor-
ing of Neoral levels during the study period was likely
done by trough levels. Recent pharmacokinetic studies
have shown that drug levels measured two hours after
Neoral ingestion (C2) correlate more closely with Neo-
ral exposure, and it is unknown what effect C2 monitoring
would have on the annualized change in GFR [17, 18]. The
finding that patients who received no form of calcineurin
inhibitor had less rapid decline in GFR compared to Neo-
ral may reflect the well-known chronic nephrotoxic effect
of calcineurin inhibitors [19].
Prospective trials have also failed to demonstrate
a difference in allograft survival between MMF- and
azathioprine-treated patients [4]. In an analysis of registry
data, Ojo et al [20] concluded that MMF-treated patients
had a 27% reduced risk of chronic allograft failure com-
pared to azathioprine-treated patients. The reported end
point of chronic allograft failure included all graft failures
after six months of transplantation that were recorded but
not confirmed to be the result of chronic rejection. How-
ever, these authors determined maintenance immuno-
suppression immediately after transplantation and did
not consider medication changes during follow-up [20].
In the current study, we found that MMF use was associ-
ated with a slightly slower decline in GFR compared with
azathioprine (0.60 mL/min/year), although the clinical
relevance of this difference is uncertain. The apparent dis-
crepancy between these two registry-based studies may
be due to the fact that our study was restricted to patients
with allograft survival of at least two years, or because our
study compared only those patients who remained on the
same medication during the entire time used to calculate
the annualized change in GFR. It is important to note
that the beneficial effect of MMF in our study is indepen-
dent of early acute rejection episodes recorded within
the first three months after transplantation, but does not
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consider the effect of late acute rejection episodes. This
is relevant because a recent analysis of registry data re-
ported a lower incidence of late acute rejection episodes
in MMF compared to azathioprine treated patients [20].
We only included early rejection episodes in our analy-
sis, because in our experience it is difficult to correlate
late rejection episodes in the USRDS database with the
recorded administration of anti-rejection drugs.
Even with the large sample size and relatively long du-
ration of follow-up in our study, the relatively small dif-
ferences in the annualized change in GFR associated with
the various immunosuppression medications in this study
would not result in significant differences in allograft sur-
vival. However, because most transplant recipients only
establish a mean baseline GFR of only 50 mL/min/1.73m2
[21], the differences in the annualized change in GFR be-
tween medications may be of clinical importance.
Our outcome measure, the annualized change in GFR,
is the recommended method to assess the progression of
kidney disease in patients with chronic kidney disease,
including transplant recipients [6]. The precision of the
estimate of the change in GFR in this study is depen-
dent on a number of factors, including the number of
GFR estimates, the duration of patient follow-up, error
in the measurement or recording of serum creatinine, and
error in the estimation of GFR [22–24]. All patients in
this study had at least three GFR measurements, and
the median follow-up in this study is longer than most
studies of GFR decline in the non-transplant population
[25]. We estimated kidney function using an equation de-
rived from the MDRD study [26] that has been recom-
mended for use in patients with chronic kidney disease,
including kidney transplant recipients [6]. In our opinion,
equations derived from the MDRD study offer several
theoretical advantages that may decrease the error asso-
ciated with estimating GFR. These include the use of a
validated method of measuring GFR (kidney clearance
of iothalamate) to derive the equation, and the use of the
most widely accepted method to measure serum creati-
nine in the United States (alkaline picrate) [27]. However,
similar to other equations that predict GFR, the MDRD
equation has not been specifically validated in a large
population of transplant recipients [28, 29].
We included the duration of follow-up in the mul-
tiple regression analysis to account for improvements
in transplant care over time (era effect) and for sur-
vival bias among patients with the longest duration of
follow-up [7]. However, because the use of tacrolimus and
MMF became prominent after 1993, we also performed
a separate analysis restricted to patients who received
transplants after this time. We found that the associations
between medication use and rates of kidney function loss
were similar in both models and therefore concluded that
our findings are unlikely to be due to residual confound-
ing by differences in transplant care over time.
Our analysis of the USRDS database provided an op-
portunity to study a large sample of transplant recipients;
however, the data set did not contain a number of factors
which may be important determinants of allograft func-
tion, including hypertension, proteinuria, and use of reno-
protective medications (e.g., ACE inhibitors, HMG-Co
reductase inhibitors) and enrollment in drug studies [30–
33, 34]. It is important to recognize that the observed dif-
ferences between medications are associations that may
be confounded by unmeasured factors such as those men-
tioned above. Administrative data sets are also limited by
data accuracy. In our analysis we limited the possibility of
patient misclassification with regard to our primary study
question by limiting our comparisons of maintenance im-
munosuppression medications to patients who were tak-
ing the same medication during the entire time period
used to calculate the annualized change in GFR. How-
ever, the exposure to calcineurin and purine metabolism
inhibitors could not be determined in a number of pa-
tients because of the strict classification method used in
the study.
CONCLUSION
The choice of maintenance calcineurin and purine
metabolism inhibitors is associated with different rates
of change in allograft function, although the differ-
ence between purine metabolism inhibitors was modest.
These differences, especially those between calcineurin
inhibitors, may be of clinical importance because of the
low baseline level of allograft function established by
most transplant recipients. However, other factors such
as the potency of immunosuppression, side effect profile,
and cost may, in individual patients, outweigh consider-
ations regarding the effect of maintenance immunosup-
pression on allograft function demonstrated in this study.
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